Ingrid Swanson Pultz

Chief Technology Officer, Mopac Biologics

Role: Associate

Site: CDL-Seattle

Stream: Computational Health

Ingrid Swanson Pultz is a Translational Advisor at the Institute for Protein Design. She was the Chief Scientific Officer of PvP Biologics, an IPD spin-out company acquired by Takeda Pharmaceuticals in 2020, and served as the CEO of PvP in its early years. Ingrid was formerly a Translational Investigator and Senior Research Fellow at the IPD, where she focused on developing the enzyme technology upon which PvP was based. For this work, Ingrid has received several competitive grants and awards, including Health Innovator of the Year from Health Innovation Northwest in 2016. She performed her graduate work on bacterial second messenger systems with Dr. Sam Miller at the University of Washington’s Department of Microbiology. While in graduate school, Ingrid was awarded the Neal Groman Award for Excellence in Teaching and founded the University of Washington’s International Genetically Engineered Machine (iGEM) team. Her current role at the IPD is to provide guidance in translating nascent technologies beyond the academic laboratory.